OncoMatch/Clinical Trials/NCT07282262
An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.
Is NCT07282262 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including PD-1/PD-L1 inhibitor and Ivosidenib for biliary tract cancer.
Treatment: Ivosidenib · Lenvatinib · PD-1/PD-L1 inhibitor — This is a multicenter, non-randomized, umbrella, open-label phase II clinical study, aiming to observe and evaluate, as well as explore the efficacy and safety of precision targeted therapy based on NGS technology for IDH1-mutated patients, specifically the combination of ivosidenib with multi-target tyrosine kinase inhibitors represented by lenvatinib or PD-1/PD-L1 in advanced biliary tract cancer patients who have failed systemic chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Biomarker criteria
Required: IDH1 mutation
Disease stage
Required: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: (Ivosidenib)
Previous treatment with Ivosidenib
Lab requirements
Blood counts
adequate hematological function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify